Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Kristian Reich; April W. Armstrong; Richard G. Langley; Susan Flavin; Bruce Randazzo; Shu Li; Ming Chun Hsu; Patrick Branigan; Andrew Blauvelt

doi:10.1016/S0140-6736(19)31773-8

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Kristian Reich, April W. Armstrong, Richard G. Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming Chun Hsu, Patrick Branigan, Andrew Blauvelt

Inernational Relations Division

科研成果: 期刊稿件 › 文章 › 同行评审

268 引用（Scopus）

源语言	英语
页（从-至）	831-839
页数	9
期刊	The Lancet
卷	394
期	10201
DOI	https://doi.org/10.1016/S0140-6736(19)31773-8
出版状态	已出版 - 9月 7 2019

!!!ASJC Scopus Subject Areas

一般医学

访问文件

10.1016/S0140-6736(19)31773-8

其它文件与链接

引用此

@article{f6f94975f2ab4a7294a13b86fc239dc6,

title = "Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial",

author = "Kristian Reich and Armstrong, {April W.} and Langley, {Richard G.} and Susan Flavin and Bruce Randazzo and Shu Li and Hsu, {Ming Chun} and Patrick Branigan and Andrew Blauvelt",

note = "Funding Information: The authors wish to thank Kristin Ruley Sharples of Janssen Scientific Affairs (Spring House, PA, USA) and Cynthia Guzzo of Kelly Service (Troy, MI, USA), for their writing and editorial support in the preparation of this manuscript, and Steven Fakharzadeh and Philippe Szapary of Janssen Research & Development, for critical review of the manuscript. This study was funded by Janssen Research & Development (Spring House, PA, USA). Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2019",

month = sep,

day = "7",

doi = "10.1016/S0140-6736(19)31773-8",

language = "English",

volume = "394",

pages = "831--839",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10201",

}

TY - JOUR

T1 - Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE)

T2 - results from a phase 3, randomised controlled trial

AU - Reich, Kristian

AU - Armstrong, April W.

AU - Langley, Richard G.

AU - Flavin, Susan

AU - Randazzo, Bruce

AU - Li, Shu

AU - Hsu, Ming Chun

AU - Branigan, Patrick

AU - Blauvelt, Andrew

N1 - Funding Information: The authors wish to thank Kristin Ruley Sharples of Janssen Scientific Affairs (Spring House, PA, USA) and Cynthia Guzzo of Kelly Service (Troy, MI, USA), for their writing and editorial support in the preparation of this manuscript, and Steven Fakharzadeh and Philippe Szapary of Janssen Research & Development, for critical review of the manuscript. This study was funded by Janssen Research & Development (Spring House, PA, USA). Publisher Copyright: © 2019 Elsevier Ltd

PY - 2019/9/7

Y1 - 2019/9/7

UR - http://www.scopus.com/inward/record.url?scp=85070205566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070205566&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(19)31773-8

DO - 10.1016/S0140-6736(19)31773-8

M3 - Article

C2 - 31402114

AN - SCOPUS:85070205566

SN - 0140-6736

VL - 394

SP - 831

EP - 839

JO - The Lancet

JF - The Lancet

IS - 10201

ER -

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

!!!ASJC Scopus Subject Areas

访问文件

其它文件与链接

指纹

引用此